TP53 and endometrial cancer: The present study aimed to describe the implementation of the ProMisE classification for routine endometrial cancer evaluation in a Brazilian tertiary public cancer center hospital, to compare it with a molecular approach of MSI and TP53 mutation, and to evaluate ProMisE impact on patients’ prognosis.